Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

Pharmacogenetics and genomics - 1 Aug 2007

Grossman Iris, Avidan Nili, Singer Clara, Goldstaub Dan, Hayardeny Liat, Eyal Eli, Ben-Asher Edna, Paperna Tamar, Pe'er Itsik, Lancet Doron, Beckmann Jacques S, Miller Ariel

Abstract excerpt

Genetic-based optimization of treatment prescription is becoming a central research focus in the management of chronic diseases, such as multiple sclerosis, which incur a prolonged drug-regimen adjustment. This study was aimed to identify genetic markers that can predict response to glatiramer acetate (Copaxone) immunotherapy for relapsing multiple sclerosis. For this purpose, we genotyped fractional cohorts of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Confidence Intervals
Share to HLA-DR Antigens

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HLA-DRB1 Chains

Share to Logistic Models

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Peptides

Share to Pharmacogenetics

Share to Placebos

Source

Identifiers

PMID: 17622942
DOI: 10.1097/FPC.0b013e3281299169

Genes

CTSS
FAS
MBP
TRB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.PMID 17622942Read ↗

HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.Semantic proximity Read ↗

Pharmacogenetics of multiple sclerosisSemantic proximity Read ↗

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.Semantic proximity Read ↗

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.Semantic proximity Read ↗

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.Semantic proximity Read ↗

[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].Semantic proximity Read ↗

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.Semantic proximity Read ↗

Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.Semantic proximity Read ↗

IFN-beta pharmacogenomics in multiple sclerosis.Semantic proximity Read ↗

Effects of HLA-DRA, HLA-DQA1 and IL-6 Gene Variations to Glatiramer Acetate Resistance in Multiple Sclerosis Patients.Semantic proximity Read ↗

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.